Ligustrazine enhances the protective effect of remifentanil on myocardial ischemia-reperfusion injury by regulating miR-211/USP47 pathway

Abstract

Purpose: To assess the effects of ligustrazine on the progression of hypoxia-reoxygenation (H/R), and explore the possible role of miR-211 in myocardial ischemia-reperfusion (I/R) injury and identify its potential targeting gene. Methods: The level of miR-211 in H/R-induced cells was detected by quantitative polymerase chain reaction. CCK-8, flow cytometry (FCM), and Western blot assays were performed to examine the effect of miR-211 and USP47 on the role of remifentanil against H/R injury. Bioinformatic analysis and luciferase and Western blot assays were performed to identify and verify the potential target of miR-211. CCK-8 and FCM assays were performed to detect the mechanism of ligustrazine and miR-211 in the protection of remifentanil against H/R-induced cells. Results: Ligustrazine enhanced the effect of remifentanil on H/R-induced cardiomyocytes. MiR-211 enhanced the protective effect of remifentanil against H/R injury. Down-regulation of USP47 enhanced the protective effect of remifentanil against H/R injury. Ligustrazine enhanced the protective effect of remifentanil against H/R injury through miR-211/USP47 pathway. Conclusion: Ligustrazine enhanced the protective effect of remifentanil on myocardial I/R injury by regulating miR-211/USP47 pathway.